Literature DB >> 15123989

Bioinformatic approaches for identification and characterization of olfactomedin related genes with a potential role in pathogenesis of ocular disorders.

Arijit Mukhopadhyay1, Sangita Talukdar, Ashima Bhattacharjee, Kunal Ray.   

Abstract

PURPOSE: To identify olfactomedin domain containing proteins, which are expressed in the eye and have similarity to myocilin, to test as potential candidates for eye diseases. Most of the mutations in myocilin causing primary open angle glaucoma are located in the olfactomedin domain. In vitro experiments demonstrated interaction between optimedin and myocilin through the conserved olfactomedin domains of the proteins in rats, and it was speculated that optimedin might have a role in the pathogenesis of ocular disorders. Hence, we aimed to identify myocilin related human proteins having conserved olfactomedin domains with potential to interact between them and examine the expression patterns in the eye by bioinformatics approaches. This endeavor would have the potential to identify new candidate genes for eye diseases in general and glaucoma in particular to be tested by wet-lab experiments.
METHODS: Proteins with homology to myocilin were selected by BLASTp at the NCBI server. cDNA sequences and corresponding genomic contigs were retrieved. Pairwise BLAST was done to investigate the gene structure. The human EST database and NEIBank were searched against the selected cDNAs to look for tissue specific expression of the transcripts.
RESULTS: The study led to the identification of three groups of proteins encoded by three different genes; Noelin 1 (9q34.3), Noelin 2 (19p13.2), and Noelin 3 (1p22) encompassing 45,575 bp, 82,679 bp, and 1,93,421 bp of the genomic sequence, respectively. Genomic structures, alternate usage of exons, and molecular evolution of the Noelins were determined. Similar structures of the genes, splicing patterns and high levels of homology shed light on the relatedness and molecular evolution of this group of olfactomedin related proteins. Strikingly, however, Noelin 1 and Noelin 3 were found to be expressed as multiple splice variants while only a single spliced transcript could be identified for Noelin 2. A human EST database search suggested the expression of all three Noelin genes in the brain but only two (Noelin 1 and Noelin 2) in the eye despite experimental evidence for expression of Noelin 3 in ocular tissue. Myocilin was determined to have similar levels (60-61%) of homology with all three Noelin gene products (Noelin 1_v1, Noelin 2_v1, and Noelin 3_v1) at the conserved olfactomedin domains.
CONCLUSIONS: Mammalian Noelin 1 evolved from its precursor, followed by evolution of Noelin 3 and Noelin 2 by gene duplication events. Myocilin might have evolved from Noelin 2 by gene duplication followed by exon fusion. Noelin 1 and Noelin 2 could be tested as candidate genes for eye diseases based on their expressions in the eye and shared olfactomedin domains with Myocilin in the C-termini of the respective proteins.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15123989

Source DB:  PubMed          Journal:  Mol Vis        ISSN: 1090-0535            Impact factor:   2.367


  15 in total

Review 1.  A molecular mechanism for glaucoma: endoplasmic reticulum stress and the unfolded protein response.

Authors:  Robert R H Anholt; Mary Anna Carbone
Journal:  Trends Mol Med       Date:  2013-07-19       Impact factor: 11.951

2.  Linkage and association of phospholipid transfer protein activity to LASS4.

Authors:  Elisabeth A Rosenthal; James Ronald; Joseph Rothstein; Ramakrishnan Rajagopalan; Jane Ranchalis; G Wolfbauer; John J Albers; John D Brunzell; Arno G Motulsky; Mark J Rieder; Deborah A Nickerson; Ellen M Wijsman; Gail P Jarvik
Journal:  J Lipid Res       Date:  2011-07-13       Impact factor: 5.922

3.  Olfactomedin 2: expression in the eye and interaction with other olfactomedin domain-containing proteins.

Authors:  Afia Sultana; Naoki Nakaya; Vladimir V Senatorov; Stanislav I Tomarev
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-04-20       Impact factor: 4.799

4.  Optimedin induces expression of N-cadherin and stimulates aggregation of NGF-stimulated PC12 cells.

Authors:  Hee-Sheung Lee; Stanislav I Tomarev
Journal:  Exp Cell Res       Date:  2006-09-28       Impact factor: 3.905

5.  Myocilin is a modulator of Wnt signaling.

Authors:  Heung-Sun Kwon; Hee-Sheung Lee; Yun Ji; Jeffrey S Rubin; Stanislav I Tomarev
Journal:  Mol Cell Biol       Date:  2009-02-02       Impact factor: 4.272

Review 6.  Molecular complexity of primary open angle glaucoma: current concepts.

Authors:  Kunal Ray; Suddhasil Mookherjee
Journal:  J Genet       Date:  2009-12       Impact factor: 1.166

7.  Olfactomedin-2 mediates development of the anterior central nervous system and head structures in zebrafish.

Authors:  Ju-Ahng Lee; Robert R H Anholt; Gregory J Cole
Journal:  Mech Dev       Date:  2007-09-29       Impact factor: 1.882

8.  Olfactomedin-like 3 (OLFML3) gene expression in baboon and human ocular tissues: cornea, lens, uvea, and retina.

Authors:  I P Rodríguez-Sánchez; M L Garza-Rodríguez; K Mohamed-Noriega; V S Voruganti; M E Tejero; I Delgado-Enciso; D C Pérez-Ibave; N E Schlabritz-Loutsevitch; J Mohamed-Noriega; M L Martinez-Fierro; D Reséndez-Pérez; S A Cole; H Cavazos-Adame; A G Comuzzie; J Mohamed-Hamsho; H A Barrera-Saldaña
Journal:  J Med Primatol       Date:  2013-02-09       Impact factor: 0.667

Review 9.  Olfactomedin domain-containing proteins: possible mechanisms of action and functions in normal development and pathology.

Authors:  Stanislav I Tomarev; Naoki Nakaya
Journal:  Mol Neurobiol       Date:  2009-06-26       Impact factor: 5.590

10.  Identification and functional characterisation of genetic variants in OLFM2 in children with developmental eye disorders.

Authors:  R Holt; S A Ugur Iseri; A W Wyatt; D A Bax; D Gold Diaz; C Santos; S Broadgate; R Dunn; J Bruty; Y Wallis; D McMullan; C Ogilvie; D Gerrelli; Y Zhang; Nicola Ragge
Journal:  Hum Genet       Date:  2016-11-14       Impact factor: 4.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.